Travere Therapeutics (TVTX) Short Interest Ratio & Short Volume $17.72 -0.75 (-4.06%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Travere Therapeutics Short Interest DataTravere Therapeutics (TVTX) has a short interest of 7.99 million shares. This marks a -1.48% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.4, indicating that it would take 4.4 days of the average trading volume of 1.38 million shares to cover all short positions.Current Short Interest7,990,000 sharesPrevious Short Interest8,110,000 sharesChange Vs. Previous Month-1.48%Dollar Volume Sold Short$139.83 millionShort Interest Ratio4.4 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares78,050,000 sharesPercentage of Shares Shorted10.24%Today's Trading Volume1,473,287 sharesAverage Trading Volume1,376,036 sharesToday's Volume Vs. Average107% Short Selling Travere Therapeutics? Sign up to receive the latest short interest report for Travere Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTVTX Short Interest Over TimeTVTX Days to Cover Over TimeTVTX Percentage of Float Shorted Over Time Ad Investors AlleyStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A small group just discovered a "backdoor" way to collect yields up to 39.70%!Click here to see this breakthrough before everyone else → Travere Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20247,990,000 shares $139.83 million -1.5%N/A4.4 $17.50 10/15/20248,110,000 shares $143.47 million +16.5%N/A4.7 $17.69 9/30/20246,960,000 shares $97.37 million -19.6%N/A4.2 $13.99 9/15/20248,660,000 shares $116.74 million -6.4%N/A6.2 $13.48 8/31/20249,250,000 shares $87.60 million -0.5%N/A7.2 $9.47 8/15/20249,300,000 shares $81.65 million -7.8%N/A8.5 $8.78 Get the Latest News and Ratings for TVTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202410,090,000 shares $96.26 million -0.1%N/A8.8 $9.54 7/15/202410,100,000 shares $99.08 million -2.1%N/A8.2 $9.81 6/30/202410,320,000 shares $84.83 million -23.1%N/A8.2 $8.22 6/15/202413,414,700 shares $96.18 million -0.4%N/A11 $7.17 5/31/202413,470,000 shares $99.95 million +0.2%N/A11.3 $7.42 5/15/202413,440,000 shares $91.39 million +4.9%N/A11 $6.80 4/30/202412,810,000 shares $70.84 million +8.6%N/A10.3 $5.53 4/15/202411,800,000 shares $74.58 million +11.3%N/A9.9 $6.32 3/31/202410,600,000 shares $81.73 million +5.3%N/A8.8 $7.71 3/15/202410,070,000 shares $75.42 million -1.9%N/A8.2 $7.49 2/29/202410,260,000 shares $77.57 million +5.1%N/A7.5 $7.56 2/15/20249,760,000 shares $85.30 million -1.7%N/A6.7 $8.74 1/31/20249,930,000 shares $88.67 million +2.3%N/A6.3 $8.93 1/15/20249,710,000 shares $92.54 million -2.1%N/A5.8 $9.53 12/31/20239,920,000 shares $89.18 million +2.9%N/A5.9 $8.99 12/15/20239,640,000 shares $83.48 million -3.1%N/A5.8 $8.66 11/30/20239,950,000 shares $62.49 million -6.7%N/A5 $6.28 11/15/202310,660,000 shares $65.77 million +21.0%N/A5.9 $6.17 10/31/20238,810,000 shares $57.09 million +0.5%N/A5.2 $6.48 10/15/20238,770,000 shares $62.27 million +4.2%N/A5.6 $7.10 9/30/20238,420,000 shares $75.27 million -6.9%N/A5.8 $8.94 9/15/20239,040,000 shares $123.76 million +5.7%N/A6.7 $13.69 8/31/20238,550,000 shares $122.09 million +5.6%N/A8.3 $14.28 8/15/20238,100,000 shares $123.12 million +0.4%N/A7.6 $15.20 7/31/20238,070,000 shares $138.72 million -2.7%N/A7.3 $17.19 7/15/20238,290,000 shares $126.92 million -2.5%N/A6.5 $15.31 6/30/20238,500,000 shares $130.56 million +11.0%N/A6.3 $15.36 6/15/20237,660,000 shares $131.75 million +4.9%N/A5.4 $17.20 5/31/20237,300,000 shares $130.60 million -3.2%N/A5.4 $17.89 5/15/20237,540,000 shares $123.20 million -4.1%N/A4.7 $16.34 4/30/20237,860,000 shares $169.54 million -3.7%N/A4.7 $21.57 4/15/20238,160,000 shares $165.81 million -4.5%N/A5.6 $20.32 3/31/20238,540,000 shares $192.06 million +14.8%N/A5.7 $22.49 3/15/20237,440,000 shares $158.25 million -1.6%N/A5.4 $21.272024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] 2/28/20237,560,000 shares $167.53 million +9.9%N/A5.7 $22.16 2/15/20236,880,000 shares $138.43 million -7.7%N/A5.8 $20.12 1/31/20237,450,000 shares $166.88 million -0.9%N/A8.8 $22.40 1/15/20237,520,000 shares $152.81 million -10.3%N/A9.1 $20.32 12/30/20228,380,000 shares $176.23 million +3.1%N/A10 $21.03 12/15/20228,130,000 shares $150.41 million -1.2%N/A9.7 $18.50 11/30/20228,230,000 shares $165.67 million +5.9%N/A10.6 $20.13 11/15/20227,770,000 shares $167.13 million -1.2%N/A10.4 $21.51 10/31/20227,860,000 shares $170.40 million +23.0%13.0%10.9 $21.68 10/15/20226,390,000 shares $132.15 million -6.2%10.6%8.4 $20.68 9/30/20226,810,000 shares $167.80 million +3.0%11.3%10.3 $24.64 9/15/20226,610,000 shares $179.79 million -0.5%11.0%9.9 $27.20 8/31/20226,640,000 shares $177.69 million -10.2%11.1%9 $26.76 8/15/20227,390,000 shares $211.28 million +7.9%12.3%9.7 $28.59 7/31/20226,850,000 shares $161.25 million +2.4%11.5%7.9 $23.54 7/15/20226,690,000 shares $163.97 million -5.0%11.2%8.4 $24.51 6/30/20227,040,000 shares $170.58 million +6.2%11.8%8.6 $24.23 6/15/20226,630,000 shares $160.18 million -10.4%11.1%8 $24.16 5/31/20227,400,000 shares $172.49 million -12.6%12.4%8.9 $23.31 5/15/20228,470,000 shares $187.86 million +3.7%14.2%9.7 $22.18 4/30/20228,170,000 shares $205.31 million +14.1%13.8%10.5 $25.13 4/15/20227,160,000 shares $212.22 million +0.7%12.1%9.3 $29.64 3/31/20227,110,000 shares $183.22 million -6.5%12.0%9.8 $25.77 3/15/20227,600,000 shares $181.72 million +29.3%12.8%11.5 $23.91 2/28/20225,880,000 shares $160.29 million -1.7%10.0%9.1 $27.26 2/15/20225,980,000 shares $171.39 million +11.4%10.5%11 $28.66 1/31/20225,370,000 shares $147.68 million +8.5%9.3%10.6 $27.50 1/15/20224,950,000 shares $136.32 million -15.5%8.5%9.3 $27.54 12/31/20215,860,000 shares $181.89 million -6.4%N/A0 $31.04 12/15/20216,260,000 shares $182.48 million +0.6%10.8%11.6 $29.15 11/30/20216,220,000 shares $177.58 million +3.0%10.7%10.5 $28.55 11/15/20216,040,000 shares $177.39 million -1.2%10.4%9.7 $29.37 10/29/20216,110,000 shares $176.03 million +0.5%10.1%5 $28.81 10/15/20216,080,000 shares $148.96 million -6.9%10.2%5.1 $24.50 9/30/20216,530,000 shares $158.35 million -5.6%10.9%5.4 $24.25 9/15/20216,920,000 shares $162.83 million -3.1%11.5%5.4 $23.53 8/31/20217,140,000 shares $155.87 million +6.7%11.9%5.5 $21.83 8/13/20216,690,000 shares $103.36 million -1.6%11.2%4.9 $15.45 7/30/20216,800,000 shares $93.50 million +2.6%11.4%8.3 $13.75 7/15/20216,630,000 shares $90.83 million -1.5%11.1%8 $13.70 6/30/20216,730,000 shares $98.19 million +23.0%11.3%8.3 $14.59 6/15/20215,470,000 shares $81.67 million +19.4%9.2%7.5 $14.93 5/28/20214,580,000 shares $69.48 million -0.4%7.7%7 $15.17 5/14/20214,600,000 shares $86.94 million -3.2%7.7%8.7 $18.90 4/30/20214,750,000 shares $117.85 million -1.5%8.0%8.2 $24.81 4/15/20214,820,000 shares $122.48 million -6.4%8.1%7.7 $25.41 3/31/20215,150,000 shares $125.25 million +20.9%8.6%8.3 $24.32 3/15/20214,260,000 shares $122.43 million +3.2%7.2%6.9 $28.74 2/26/20214,130,000 shares $122.66 million -1.7%7.0%6.9 $29.70 2/12/20214,200,000 shares $116.72 million -0.7%7.4%7.3 $27.792024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] 1/29/20214,230,000 shares $109.09 million -2.8%8.4%8.9 $25.79 1/15/20214,350,000 shares $126.67 million No Change8.6%11.1 $29.12 TVTX Short Interest - Frequently Asked Questions What is Travere Therapeutics' current short interest? Short interest is the volume of Travere Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 7,990,000 shares of TVTX short. Learn More on Travere Therapeutics' current short interest. What is a good short interest ratio for Travere Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TVTX shares currently have a short interest ratio of 4.0. Learn More on Travere Therapeutics's short interest ratio. Which institutional investors are shorting Travere Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Travere Therapeutics: Jane Street Group LLC, and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Travere Therapeutics' short interest increasing or decreasing? Travere Therapeutics saw a decline in short interest during the month of October. As of October 31st, there was short interest totaling 7,990,000 shares, a decline of 1.5% from the previous total of 8,110,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Travere Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Travere Therapeutics: Harrow, Inc. (7.27%), Rigel Pharmaceuticals, Inc. (3.83%), Omeros Co. (21.64%), Nuvalent, Inc. (12.72%), Arcellx, Inc. (9.74%), ADMA Biologics, Inc. (6.43%), Krystal Biotech, Inc. (12.00%), Avidity Biosciences, Inc. (12.29%), BridgeBio Pharma, Inc. (11.71%), Biohaven Ltd. (9.05%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Travere Therapeutics stock? Short selling TVTX is an investing strategy that aims to generate trading profit from Travere Therapeutics as its price is falling. TVTX shares are trading down $0.75 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Travere Therapeutics? A short squeeze for Travere Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TVTX, which in turn drives the price of the stock up even further. How often is Travere Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TVTX, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Harrow Short Interest Data Rigel Pharmaceuticals Short Interest Data Omeros Short Interest Data Nuvalent Short Interest Data Arcellx Short Interest Data ADMA Biologics Short Interest Data Krystal Biotech Short Interest Data Avidity Biosciences Short Interest Data BridgeBio Pharma Short Interest Data Biohaven Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:TVTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.